Company: NYXH
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0001410578-25-000398
Chunk: 15

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 15
---
 a new ATM program pursuant to the sales agreement with Cantor. During 2023 we carried out several capital raises for a total amount of €18.9 million. During 2024 we carried out additional capital raises for a total amount of €110.6 million. All of our shares were admitted to trading on The Nasdaq Global Market under the symbol “NYXH”. As of December 31, 2024, we had cash and cash equivalents of €34.2 million and financial assets of €51.4 million and an accumulated deficit of €217.7 million. Based on cash flow forecasts for the upcoming years, which include significant expenses and cash outflows in relation to -among others- the ongoing clinical trials, the continuation of research and development projects, and the scaling-up of the Company’s manufacturing facilities, in support of the Company’s commercial launch of its Genio product in the United States, the Company believes that this cash position will be sufficient to meet the Company’s capital requirements and fund its operations for at least 12 months as from the date of this Consolidated Financial Statements. See the report of our independent registered public accounting firm and Note 5.1 to our consolidated financial statements found elsewhere in this Annual Report.
Cash Flows
The following table summarizes the results of our cash flows for the years ended December 31, 2023 and 2024.
​

                     ​                         ​    ​        ​        ​      ​        ​    
-------------------------------------------------------------------------------------------
​                                              ​   Year ended December 31,                 
​                                              ​   2024              ​      2023           
​                                              ​   (In thousands)                          
Net cash used in operating activities              €      (49,226)          €      (44,778)
Net cash from (used in) investing activities   ​          (16,325)   ​               32,011
Net cash from (used in) financing activities   ​            77,439   ​               16,858
Effects of exchange rate changes               ​   688               ​                (369)
Change in cash and cash equivalents            ​   €        12,576   ​      €         3,722
​
Operating activities. Net cash used in operations was €49.2 million in 2024 compared to €44.8 million in 2023. The increase of cash used in operations of €4.4 was primarily due to higher losses of €11.8 million that were mainly attributable to increased research and development expenses